Skip to content

Author

N. Scarmeas

We have 5 of 285 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Polygenic Risk Scores in Alzheimer’s Disease: A Cross-Scale View from Genes to Brain and Behavior

Alzheimer’s disease (AD) is a genetically complex disorder in which inherited susceptibility is distributed across rare high-impact variants, the apolipoprotein E (APOE) locus, and a broad polygenic background of common risk alleles. Polygenic risk scores (PRSs) provide a quantitative framework for summarizing this dis...

Efthalia Angelopoulou, Ioannis Stamelos, Stefanos N. Sampatakakis et al. · 0 citations
Open access Aug 2026

Diet-responsive proteogenomic effects following short-term restriction of animal products in humans

The effect of diet on genetic regulation in humans remains largely unexplored. Here, we investigate gene-diet interactions in a unique group of healthy individuals (N = 200) who alternate between omnivory and dietary restriction of animal products for religious reasons. Using longitudinal proteomic and genotype data, w...

Alexandros Simistiras, O. Bocher, C. Emmanouil et al. · 0 citations
Sep 2026

Serum metabolite signature of the mediterranean diet adherence and cognitive function: Evidence from two cohorts.

BACKGROUND AND AIMS The Mediterranean diet (MD) has been consistently associated with favorable cognitive outcomes. However, reliance on self-reported dietary assessment limits accurate characterization of diet-health associations. Circulating metabolites may capture the endogenous metabolic imprint of habitual dietary...

C. Papandreou, Vasiliki-Amaryllis Skyfa, K. Tsilidis et al. · 0 citations
Open access Sep 2026

APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers’s disease

Understanding of the genetic architecture of AD in the context of its main genetic driver is improved, and APOE-stratified insights may help understand and overcome side effects, inform clinical trial enrollment strategies, and create the scientific basis for targeted, mechanism-driven therapies in neurodegenerative di...

J. Thomassen, H. Leonard, Brittany Ulms et al. · 0 citations
Open access Aug 2026

Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk.

It is concluded that rare coding CNVs in a proportion of AD-associated genes and 22q11.21 duplication as a strong AD-risk-decreasing factor increase AD risk and Conversely, 22q11.21 duplication as a strong AD-risk-decreasing factor is identified.

O. Quenez, Catherine Schramm, K. Cassinari et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.